$INVA
Innoviva, Inc. Stock $inva

$inva Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023005168 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$76.37M	$65.80M	$331.3M
YoY Change	23618.01%	-38.89%	17917.35%
Cost Of Revenue	$10.35M	$10.11M	$13.79M
YoY Change
Gross Profit	$66.02M	$55.69M	$317.5M
YoY Change
Gross Profit Margin	86.45%	84.63%	95.84%
Selling, General & Admin	$19.74M	$17.45M	$63.54M
YoY Change	203.99%	460.68%	292.52%
% of Gross Profit	29.89%	31.34%	20.01%
Research & Development	$12.59M	$9.985M	$41.43M
YoY Change	115.62%	24862.5%	7093.06%
% of Gross Profit	19.07%	17.93%	13.05%
Depreciation & Amortization	$7.284M	$7.005M	$19.51M
YoY Change	108.05%	102.69%	41.06%
% of Gross Profit	11.03%	12.58%	6.14%
Operating Expenses	$32.32M	$31.51M	$105.0M
YoY Change	162.15%	899.33%	526.2%
Operating Profit	$33.70M	$24.18M	$212.6M
YoY Change	-56.64%		-43.33%
Interest Expense	$4.427M	-$86.25M	$15.79M
YoY Change	47.08%	85.68%	-17.21%
% of Operating Profit	13.14%	-356.67%	7.43%
Other Income/Expense, Net	-$1.346M	-$2.623M	-$3.373M
YoY Change	438.4%	64.97%	-6.98%
Pretax Income	$41.14M	-$64.69M	$286.9M
YoY Change	-8.0%	-214.51%	-35.56%
Income Tax	$6.300M	$3.626M	$66.69M
% Of Pretax Income	15.31%		23.24%
Net Earnings	$34.87M	-$68.31M	$220.3M
YoY Change	-7.91%	-760.36%	-40.28%
Net Earnings / Revenue	45.65%	-103.82%	66.48%
Basic Earnings Per Share	$0.51		$3.07
Diluted Earnings Per Share	$0.42	-$0.71	$2.37
COMMON SHARES
Basic Shares Outstanding	68.13M	69.78M	69.64M
Diluted Shares Outstanding	89.79M		95.25M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$144.0M	$291.0M	$291.0M
YoY Change	-33.56%	44.42%	44.42%
Cash & Equivalents	$144.0M	$291.0M	$291.0M
Short-Term Investments
Other Short-Term Assets	$2.821M	$2.933M	$32.49M
YoY Change	46.17%	4090.0%	2161.1%
Inventory	$49.65M	$55.90M	$55.90M
Prepaid Expenses
Receivables	$75.80M	$64.07M	$64.07M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$296.4M	$443.5M	$443.5M
YoY Change	-6.73%	41.39%	41.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$180.0K	$170.0K	$3.435M
YoY Change	-5.76%	1316.67%	28525.0%
Goodwill	$27.90M	$26.70M
YoY Change	403.25%
Intangibles	$248.3M	$252.9M
YoY Change	136.49%
Long-Term Investments	$455.9M	$403.0M	$403.0M
YoY Change	-16.27%	-16.71%	-16.71%
Other Assets	$3.893M	$4.299M	$4.299M
YoY Change	1143.77%	38981.82%	-75.34%
Total Long-Term Assets	$833.3M	$788.0M	$788.0M
YoY Change	5.53%	28.6%	28.6%
TOTAL ASSETS
Total Short-Term Assets	$296.4M	$443.5M	$443.5M
Total Long-Term Assets	$833.3M	$788.0M	$788.0M
Total Assets	$1.130B	$1.231B	$1.231B
YoY Change	2.01%	32.93%	32.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.933M	$2.939M	$2.939M
YoY Change	228.15%	10785.19%	10785.19%
Accrued Expenses	$29.96M	$33.59M	$33.59M
YoY Change	162.7%	481.11%	481.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$96.19M	$96.19M
YoY Change	-100.0%
Total Short-Term Liabilities	$38.14M	$135.0M	$135.0M
YoY Change	-65.08%	2224.23%	2224.23%
LONG-TERM LIABILITIES
Long-Term Debt	$444.7M	$444.2M	$444.2M
YoY Change	0.44%	12.55%	12.55%
Other Long-Term Liabilities	$70.13M	$70.92M	$80.79M
YoY Change	2025.89%
Total Long-Term Liabilities	$514.8M	$515.1M	$525.0M
YoY Change	15.42%	30.52%	33.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.14M	$135.0M	$135.0M
Total Long-Term Liabilities	$514.8M	$515.1M	$525.0M
Total Liabilities	$553.0M	$650.1M	$665.7M
YoY Change	-0.41%	62.33%	30.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$170.0M	-$204.9M
YoY Change	-57.82%	-55.08%
Common Stock	$1.125B	$1.165B
YoY Change	-4.92%	-7.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$561.5M	$565.8M	$565.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.130B	$1.231B	$1.231B
YoY Change	2.01%	32.93%	32.93%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$34.87M	-$68.31M	$220.3M
YoY Change	-7.91%	-760.36%	-40.28%
Depreciation, Depletion And Amortization	$7.284M	$7.005M	$19.51M
YoY Change	108.05%	102.69%	41.06%
Cash From Operating Activities	$25.68M	$8.899M	$201.7M
YoY Change	-73.82%	-90.95%	-44.55%
INVESTING ACTIVITIES
Capital Expenditures	$33.00K	$34.00K	$67.00K
YoY Change	266.67%
Acquisitions
YoY Change
Other Investing Activities	-$35.69M	-$8.644M	-$56.57M
YoY Change	-1871.17%	-56.57%	-70.38%
Cash From Investing Activities	-$35.72M	-$8.678M	-$56.63M
YoY Change	-75.05%	-56.4%	-229.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$8.133M
YoY Change			-97.93%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-137.0M	-10.00M	-55.57M
YoY Change	-327.02%	-17.11%	-87.72%
NET CHANGE
Cash From Operating Activities	25.68M	8.899M	201.7M
Cash From Investing Activities	-35.72M	-8.678M	-56.63M
Cash From Financing Activities	-137.0M	-10.00M	-55.57M
Net Change In Cash	-147.0M	-9.780M	89.52M
YoY Change	-1062.23%	-114.73%	-299.11%
FREE CASH FLOW
Cash From Operating Activities	$25.68M	$8.899M	$201.7M
Capital Expenditures	$33.00K	$34.00K	$67.00K
Free Cash Flow	$25.65M	$8.865M	$201.7M
YoY Change	-73.85%	-90.99%	-44.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5807000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	444180000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	394653000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	70918000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5771000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0
CY2022Q4	inva	Income Tax Payable Non Current IncomeTaxPayableNonCurrent	9872000
CY2021Q4	inva	Income Tax Payable Non Current IncomeTaxPayableNonCurrent	0
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69188000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69188000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69566000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69566000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	692000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	696000
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	32005000
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	32005000
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	393829000
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	393829000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1163836000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1264024000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-204911000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-456148000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	565788000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	414743000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	0
CY2021Q4	us-gaap	Minority Interest MinorityInterest	111192000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	565788000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1231497000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	525935000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	926395000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	331339000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	336794000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	391866000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	63538000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16187000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13883000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41432000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	576000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1788000
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001080014
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q4	inva	Capitalized Fees Paid Remaining Estimated Amortization Year Five CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive	13800000
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-30319
CY2022	dei	Entity Registrant Name EntityRegistrantName	INNOVIVA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3265960
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1350 Old Bayshore Highway, Suite 400
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Burlingame
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94010
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	238-9600
CY2022	dei	Security12b Title Security12bTitle	Common Stock $0.01 Par Value
CY2022	dei	Trading Symbol TradingSymbol	INVA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	923930805000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68126089
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	619000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4359000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4152000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2094000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	96193000
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	154000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	21207000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1009000
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291049000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201525000
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	9401000
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0
CY2022Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	54672000
CY2021Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	110711000
CY2022Q4	us-gaap	Inventory Net InventoryNet	55897000
CY2021Q4	us-gaap	Inventory Net InventoryNet	0
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29559000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1367000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2933000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	70000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	443511000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	313673000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	170000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	403013000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	483845000
CY2022Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	97607000
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	111430000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3265000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97000
CY2022Q4	us-gaap	Goodwill Goodwill	26713000
CY2021Q4	us-gaap	Goodwill Goodwill	0
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	252919000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	17327000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4299000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11000
CY2022Q4	us-gaap	Assets Assets	1231497000
CY2021Q4	us-gaap	Assets Assets	926395000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2939000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8022000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	134968000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5581000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2022	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	266696000
CY2021	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20662000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-161749000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	84392000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	49511000
CY2022	inva	Gain Loss On Other Investments GainLossOnOtherInvestments	8462000
CY2021	inva	Gain Loss On Other Investments GainLossOnOtherInvestments	6638000
CY2020	inva	Gain Loss On Other Investments GainLossOnOtherInvestments	766000
CY2022	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	6369000
CY2021	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	1839000
CY2020	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	1524000
CY2022	us-gaap	Interest Expense InterestExpense	15789000
CY2021	us-gaap	Interest Expense InterestExpense	19070000
CY2020	us-gaap	Interest Expense InterestExpense	18331000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3373000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3626000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-348000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	44390000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	-53410000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	-17451000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	286949000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	445276000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	354245000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66687000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	76439000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	60431000
CY2022	us-gaap	Profit Loss ProfitLoss	220262000
CY2021	us-gaap	Profit Loss ProfitLoss	368837000
CY2020	us-gaap	Profit Loss ProfitLoss	293814000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6341000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	102983000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	69412000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	213921000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	265854000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	224402000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.21
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.37
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.87
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.02
CY2021	us-gaap	Profit Loss ProfitLoss	368837000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69644000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82062000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101320000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95248000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94310000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113554000
CY2022	us-gaap	Profit Loss ProfitLoss	220262000
CY2021	us-gaap	Profit Loss ProfitLoss	368837000
CY2020	us-gaap	Profit Loss ProfitLoss	293814000
CY2022	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2021	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2020	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	27000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	220262000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	368837000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	293787000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	6341000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	102983000
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	69412000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	213921000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	265854000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	224375000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342116000
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	30474000
CY2020	inva	Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity	366000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	344000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1698000
CY2020	us-gaap	Profit Loss ProfitLoss	293814000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	607837000
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	59457000
CY2021	inva	Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity	-259000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1109000
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	394149000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2017000
CY2021	us-gaap	Profit Loss ProfitLoss	368837000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	525935000
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	69811000
CY2022	inva	Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis	38471000
CY2022	inva	Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity	-2000
CY2022	inva	Derecognition Of Noncontrolling Interests Upon Sale Of Trc DerecognitionOfNoncontrollingInterestsUponSaleOfTrc	-61226000
CY2022	inva	Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest	-42162000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	288000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	16585000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3000
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	8503000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7347000
CY2020	us-gaap	Profit Loss ProfitLoss	293814000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25006000
CY2022	us-gaap	Profit Loss ProfitLoss	220262000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	565788000
CY2022	us-gaap	Profit Loss ProfitLoss	220262000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	76432000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	60420000
CY2022	inva	Amortization Of Capitalized Fees And Depreciation Of Property And Equipment AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment	13931000
CY2021	inva	Amortization Of Capitalized Fees And Depreciation Of Property And Equipment AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment	13832000
CY2020	inva	Amortization Of Capitalized Fees And Depreciation Of Property And Equipment AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment	13840000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5581000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2022	inva	Fair Value Adjustments Included In Cost Of Product Sales FairValueAdjustmentsIncludedInCostOfProductSales	10023000
CY2021	inva	Fair Value Adjustments Included In Cost Of Product Sales FairValueAdjustmentsIncludedInCostOfProductSales	0
CY2020	inva	Fair Value Adjustments Included In Cost Of Product Sales FairValueAdjustmentsIncludedInCostOfProductSales	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7347000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2017000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1698000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2055000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9136000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8397000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-161749000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	84392000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	49511000
CY2022	inva	Unrealized Other Gain Loss On Investments UnrealizedOtherGainLossOnInvestments	8462000
CY2021	inva	Unrealized Other Gain Loss On Investments UnrealizedOtherGainLossOnInvestments	4917000
CY2020	inva	Unrealized Other Gain Loss On Investments UnrealizedOtherGainLossOnInvestments	766000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20662000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	266696000
CY2021	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	0
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	0
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	343000
CY2022	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	0
CY2021	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	0
CY2020	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	135000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3402000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	259000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-21000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3525000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-13319000
CY2021	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	16780000
CY2020	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	14504000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-280000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	21350000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-203000
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	678000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3341000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	92000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-39000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	56000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11913000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-257000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	804000
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	207000
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-755000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	10026000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	201726000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	363813000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	313113000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	86000000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12943000
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	58725000
CY2021	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	66278000
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	87981000
CY2022	inva	Purchases Of Equity Investments Managed By Isp Fund Lp PurchasesOfEquityInvestmentsManagedByIspFundLp	60910000
CY2021	inva	Purchases Of Equity Investments Managed By Isp Fund Lp PurchasesOfEquityInvestmentsManagedByIspFundLp	190970000
CY2020	inva	Purchases Of Equity Investments Managed By Isp Fund Lp PurchasesOfEquityInvestmentsManagedByIspFundLp	14877000
CY2022	inva	Purchases Of Trading Security Managed By Isp Fund Lp PurchasesOfTradingSecurityManagedByIspFundLp	50000000
CY2021	inva	Purchases Of Trading Security Managed By Isp Fund Lp PurchasesOfTradingSecurityManagedByIspFundLp	0
CY2020	inva	Purchases Of Trading Security Managed By Isp Fund Lp PurchasesOfTradingSecurityManagedByIspFundLp	0
CY2022	inva	Sale Of Equity Investments Managed By Isp Fund Lp SaleOfEquityInvestmentsManagedByIspFundLp	24281000
CY2021	inva	Sale Of Equity Investments Managed By Isp Fund Lp SaleOfEquityInvestmentsManagedByIspFundLp	21440000
CY2020	inva	Sale Of Equity Investments Managed By Isp Fund Lp SaleOfEquityInvestmentsManagedByIspFundLp	0
CY2022	inva	Purchase And Sale Of Other Investments Managed By Isp Fund Lp PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp	23371000
CY2021	inva	Purchase And Sale Of Other Investments Managed By Isp Fund Lp PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp	-279530000
CY2020	inva	Purchase And Sale Of Other Investments Managed By Isp Fund Lp PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp	285123000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2022	inva	Net Proceeds From Sale Of Variable Interest Entity Equity NetProceedsFromSaleOfVariableInterestEntityEquity	248191000
CY2021	inva	Net Proceeds From Sale Of Variable Interest Entity Equity NetProceedsFromSaleOfVariableInterestEntityEquity	0
CY2020	inva	Net Proceeds From Sale Of Variable Interest Entity Equity NetProceedsFromSaleOfVariableInterestEntityEquity	0
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	23070000
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
CY2022	inva	Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired	159103000
CY2021	inva	Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired	0
CY2020	inva	Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56634000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	43722000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-314937000
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	69811000
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	59457000
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	30474000
CY2022	inva	Purchase Of Entasis Noncontrolling Interest PurchaseOfEntasisNoncontrollingInterest	43910000
CY2021	inva	Purchase Of Entasis Noncontrolling Interest PurchaseOfEntasisNoncontrollingInterest	0
CY2020	inva	Purchase Of Entasis Noncontrolling Interest PurchaseOfEntasisNoncontrollingInterest	0
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8503000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	394149000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	82000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	60000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	92000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	370000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1169000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	436000
CY2022	inva	Net Proceeds From Issuance Of Variable Interest Entity Equity NetProceedsFromIssuanceOfVariableInterestEntityEquity	0
CY2021	inva	Net Proceeds From Issuance Of Variable Interest Entity Equity NetProceedsFromIssuanceOfVariableInterestEntityEquity	0
CY2020	inva	Net Proceeds From Issuance Of Variable Interest Entity Equity NetProceedsFromIssuanceOfVariableInterestEntityEquity	345000
CY2022	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	165131000
CY2021	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	0
CY2020	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	0
CY2022	inva	Purchases Of Capped Call Options Associated With Convertible Senior Notes PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes	21037000
CY2021	inva	Purchases Of Capped Call Options Associated With Convertible Senior Notes PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes	0
CY2020	inva	Purchases Of Capped Call Options Associated With Convertible Senior Notes PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes	0
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	252536000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-55568000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-452497000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-29785000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	89524000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44962000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31609000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201525000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246487000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	278096000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291049000
CY2022	inva	Number Of Customers NumberOfCustomers	3
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201525000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246487000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	11736000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9933000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9933000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	53855000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2022	inva	Non Cash Activity NonCashActivity	-28228000
CY2021	inva	Non Cash Activity NonCashActivity	0
CY2020	inva	Non Cash Activity NonCashActivity	0
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Management’s Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (“API”) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK’s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts’ or investors’ expectations, due to a number of important factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">We also started recognizing revenue from product sales as a result of our acquisition of La Jolla Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> of our customers each account for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. These same customers account for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">23</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in “Accounts receivables, net” on our consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p>
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.37
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.87
CY2022Q4	inva	Capitalized Fee Paid Estimated Useful Life CapitalizedFeePaidEstimatedUsefulLife	P15Y
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.02
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	213921000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	265854000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	224402000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	225569000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	270590000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	229119000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69644000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82062000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101320000
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	108000
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	59000
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	45000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95248000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94310000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113554000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.21
CY2022Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	97607000
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	111430000
CY2022	inva	Capitalized Fees Paid Weighted Average Useful Life CapitalizedFeesPaidWeightedAverageUsefulLife	P7Y1M6D
CY2022Q4	inva	Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths	13800000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	930000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	979000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1193000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	263469000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	263469000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	145132000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	145132000
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Capitalized Contract Cost Gross CapitalizedContractCostGross	220000000
CY2021Q4	us-gaap	Capitalized Contract Cost Gross CapitalizedContractCostGross	220000000
CY2022Q4	us-gaap	Capitalized Contract Cost Accumulated Amortization CapitalizedContractCostAccumulatedAmortization	122393000
CY2022Q4	inva	Capitalized Fees Paid Remaining Estimated Amortization Year Two CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo	13800000
CY2022Q4	inva	Capitalized Fees Paid Remaining Estimated Amortization Yearthree CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree	13800000
CY2022Q4	inva	Intangible Assets Collaboration Agreement Gross IntangibleAssetsCollaborationAgreementGross	35400000
CY2022Q4	inva	Intangible Assets Collaboration Agreement Net IntangibleAssetsCollaborationAgreementNet	35400000
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	258500000
CY2021Q4	us-gaap	Capitalized Contract Cost Accumulated Amortization CapitalizedContractCostAccumulatedAmortization	108570000
CY2022Q4	inva	Capitalized Fees Paid Remaining Estimated Amortization Year Four CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour	13800000
CY2022Q4	inva	Capitalized Fees Paid Remaining Estimated Amortization After Year Five CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive	28600000
CY2022Q4	us-gaap	Goodwill Goodwill	26700000
CY2022Q4	inva	Intangible Assets Marketed Products Gross IntangibleAssetsMarketedProductsGross	151000000
CY2022Q4	inva	Intangible Assets Marketed Products Accumulated Amortization IntangibleAssetsMarketedProductsAccumulatedAmortization	-5581000
CY2022Q4	inva	Intangible Assets In Process Research And Development Gross IntangibleAssetsInProcessResearchAndDevelopmentGross	72100000
CY2022Q4	inva	Intangible Assets Marketed Products Net IntangibleAssetsMarketedProductsNet	145419000
CY2022Q4	inva	Intangible Assets In Process Research And Development Net IntangibleAssetsInProcessResearchAndDevelopmentNet	72100000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-5581000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	252919000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5600000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5757000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	25052000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	25088000
CY2022Q4	us-gaap	Inventory Net InventoryNet	55897000
CY2022Q4	inva	Accrued Contract Manufacturing Liability AccruedContractManufacturingLiability	8382000
CY2021Q4	inva	Accrued Contract Manufacturing Liability AccruedContractManufacturingLiability	0
CY2022Q4	inva	Accrued Clinical Liability AccruedClinicalLiability	692000
CY2021Q4	inva	Accrued Clinical Liability AccruedClinicalLiability	0
CY2022Q4	inva	Accrued Research Liability AccruedResearchLiability	349000
CY2021Q4	inva	Accrued Research Liability AccruedResearchLiability	0
CY2022Q4	inva	Accrued Professional Services AccruedProfessionalServices	3977000
CY2021Q4	inva	Accrued Professional Services AccruedProfessionalServices	894000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1316000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	106000
CY2022Q4	inva	Deferred Royalty Obligation Current DeferredRoyaltyObligationCurrent	2639000
CY2021Q4	inva	Deferred Royalty Obligation Current DeferredRoyaltyObligationCurrent	0
CY2022Q4	inva	Accrued License Fees And Royalties AccruedLicenseFeesAndRoyalties	943000
CY2021Q4	inva	Accrued License Fees And Royalties AccruedLicenseFeesAndRoyalties	0
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	2909000
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	9000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	21207000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1009000
CY2022Q4	inva	Deferred Royalty Obligation Non Current DeferredRoyaltyObligationNonCurrent	67947000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2376000
CY2022Q4	inva	Contingent Value Rights Liability ContingentValueRightsLiability	595000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	70918000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7347000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2017000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1698000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7347000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2017000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1698000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8714000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	549704000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	433484000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	9331000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	38831000
CY2022Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	540373000
CY2021Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	394653000
CY2022Q4	us-gaap	Debt Current DebtCurrent	96193000
CY2021Q4	us-gaap	Debt Current DebtCurrent	0
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	444180000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	394653000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	96204000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	192500000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	261000000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	40822000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	549704000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1585000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	155000
CY2022	us-gaap	Lease Cost LeaseCost	1740000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	790000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3323000
CY2022	inva	Right Of Use Assets Obtained Through Acquistions RightOfUseAssetsObtainedThroughAcquistions	1185000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2022	inva	Operating Lease Weighted Average Incremental Borrowing Rate OperatingLeaseWeightedAverageIncrementalBorrowingRate	0.075
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3265000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1316000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	106000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2376000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3692000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	106000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1542000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1269000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1289000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4100000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	408000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3692000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	464000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	41286000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	26026000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	70893000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	60408000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-625000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5539000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	12000
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	25401000
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	76432000
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	60420000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66687000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	76439000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	60431000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	58928000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	93507000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	74392000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1414000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	848000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-26000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-2453000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1260000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	7468000
CY2021	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	-21626000
CY2020	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	-14577000
CY2022	us-gaap	Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	-8897000
CY2021	us-gaap	Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0
CY2020	us-gaap	Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-125000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1129000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	839000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13180000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1321000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-197000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66687000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	76439000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	60431000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	149646000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	64813000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	21230000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	53467000
CY2022Q4	inva	Deferred Tax Assets Unrealized Losses On Investment Net DeferredTaxAssetsUnrealizedLossesOnInvestmentNet	6032000
CY2021Q4	inva	Deferred Tax Assets Unrealized Losses On Investment Net DeferredTaxAssetsUnrealizedLossesOnInvestmentNet	0
CY2022Q4	inva	Deferred Tax Assets Deferred Royalty Obligation Net DeferredTaxAssetsDeferredRoyaltyObligationNet	17404000
CY2021Q4	inva	Deferred Tax Assets Deferred Royalty Obligation Net DeferredTaxAssetsDeferredRoyaltyObligationNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8527000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	743000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	202839000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	119023000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	144808000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	64744000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	58031000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	54279000
CY2022Q4	inva	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	-50587000
CY2021Q4	inva	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	-9158000
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	0
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	27794000
CY2022Q4	inva	Deferred Tax Liabilities Inventory Fair Value Adjustment DeferredTaxLiabilitiesInventoryFairValueAdjustment	-12410000
CY2021Q4	inva	Deferred Tax Liabilities Inventory Fair Value Adjustment DeferredTaxLiabilitiesInventoryFairValueAdjustment	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-805000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5771000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	17327000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15342000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	157000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15185000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	313000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14872000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1452000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16324000
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	San Jose, California

Files In Submission

Name	View Source	Status
0000950170-23-005168-index-headers.html	Edgar Link	pending
0000950170-23-005168-index.html	Edgar Link	pending
0000950170-23-005168.txt	Edgar Link	pending
0000950170-23-005168-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img11029722_0.jpg	Edgar Link	pending
img11029722_1.jpg	Edgar Link	pending
img11029722_10.jpg	Edgar Link	pending
img11029722_11.jpg	Edgar Link	pending
img11029722_12.jpg	Edgar Link	pending
img11029722_13.jpg	Edgar Link	pending
img11029722_14.jpg	Edgar Link	pending
img11029722_2.jpg	Edgar Link	pending
img11029722_3.jpg	Edgar Link	pending
img11029722_4.jpg	Edgar Link	pending
img11029722_5.jpg	Edgar Link	pending
img11029722_6.jpg	Edgar Link	pending
img11029722_7.jpg	Edgar Link	pending
img11029722_8.jpg	Edgar Link	pending
img11029722_9.jpg	Edgar Link	pending
inva-20221231.htm	Edgar Link	pending
inva-20221231.xsd	Edgar Link	pending
inva-20221231_lab.xml	Edgar Link	unprocessable
inva-20221231_def.xml	Edgar Link	unprocessable
inva-20221231_htm.xml	Edgar Link	completed
inva-ex21_1.htm	Edgar Link	pending
inva-ex23_1.htm	Edgar Link	pending
inva-ex23_2.htm	Edgar Link	pending
inva-ex31_1.htm	Edgar Link	pending
inva-ex31_2.htm	Edgar Link	pending
inva-ex32.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
inva-20221231_cal.xml	Edgar Link	unprocessable
inva-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INVA
Innoviva, Inc. Stock $inva

2023 Q1 Form 10-K Financial Statement

#000095017023005168 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INVA Innoviva, Inc. Stock $inva

2023 Q1 Form 10-K Financial Statement

#000095017023005168 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INVA
Innoviva, Inc. Stock $inva